



AUTHOR CORRECTION

Author Correction: Autophagy inhibitors increase the susceptibility of KRAS-mutant human colorectal cancer cells to a combined treatment of 2-deoxy-*D*-glucose and lovastatin

Xiao-ming Huang¹, Jia-jun Huang¹, Jing-jing Du¹, Na Zhang¹, Ze Long¹, You Yang¹, Fang-fang Zhong¹, Bo-wen Zheng¹, Yun-fu Shen¹, Zhe Huang¹, Xiang Qin¹, Jun-he Chen¹, Qian-yu Lin¹, Wan-jun Lin¹ and Wen-zhe Ma¹

Acta Pharmacologica Sinica (2022) 43:1881; <https://doi.org/10.1038/s41401-021-00834-x>

Correction to: *Acta Pharmacologica Sinica* <https://doi.org/10.1038/s41401-021-00612-9>, published online 19 February 2021

The authors apologize that in Fig. 5d, the western blotting bands of HCT116 cells treated with 2DG (5 mM) and different concentrations of lovastatin were the same as cells treated with lovastatin

(10 μ M) and different concentrations of 2DG, which was misplaced inadvertently. The correct figure is reproduced and presented. The conclusions are not affected by this correction. We sincerely apologize for our mistakes and any inconvenience this might have caused.




Fig. 5 d Representative immunoblots showing LC3 and Beclin-1 from HCT116 cells treated with either 2DG (5 mM) and different concentrations of lovastatin or lovastatin (10 μ M) and different concentrations of 2DG for 48 h.

¹State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Macao, China
Correspondence: Wen-zhe Ma (wzma@must.edu.mo)